BRAF inhibition in refractory hairy-cell leukemia
To the Editor: Hairy-cell leukemia (HCL) is a mature B-cell lymphoid cancer that is commonly treated with purine analogues.1 Virtually all patients with HCL carry the BRAF V600E mutation, which constitutively activates the MEK-ERK pathway and which can be inhibited in vitro by the mutation-specific...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 24, 2012
|
| In: |
The New England journal of medicine
Year: 2012, Volume: 366, Issue: 21, Pages: 2038-2040 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMc1202124 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMc1202124 Verlag, Volltext: https://doi.org/10.1056/NEJMc1202124 
|
| Author Notes: | Sascha Dietrich, Hanno Glimm, Mindaugas Andrulis, Christof von Kalle, Anthony D. Ho, Thorsten Zenz |
| Summary: | To the Editor: Hairy-cell leukemia (HCL) is a mature B-cell lymphoid cancer that is commonly treated with purine analogues.1 Virtually all patients with HCL carry the BRAF V600E mutation, which constitutively activates the MEK-ERK pathway and which can be inhibited in vitro by the mutation-specific BRAF inhibitor PLX-4720.2 BRAF mutations have been identified in melanoma but are found across cancers.3 An inhibitor of mutated BRAF (vemurafenib) has transformed the treatment of melanoma. It is unclear whether this clinical efficacy can be extrapolated to other cancers.4,5 We used vemurafenib in a patient with refractory HCL and a pressing need for . . . |
|---|---|
| Item Description: | Gesehen am 29.03.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMc1202124 |